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Résumé 
Etude de la valeur pronostique de la biopsie du ganglion sentinelle dans 
une étude prospective monocentrique de 327 patients atteints de 
mélanome malin 
But 
Il s'agit de confirmer la validité de la biopsie du ganglion sentinelle, d'en définir la 
morbidité, d'investiguer les facteurs prédictifs pour le statut du ganglion sentinelle ainsi 
que de déterminer les facteurs pronostiques pour la survie sans récidive et la survie 
spécifique liée à la maladie. 
Matériel et méthode 
D'octobre 1997 à décembre 2004, 327 patients consécutifs présentant un mélanome cutané 
primaire des membres, du tronc et de la tête, sans adénopathie clinique ni métastase à 
distance ont été inclus. La biopsie du ganglion sentinelle a été réalisée selon la triple 
technique (lymphoscintigraphie, colorant bleu vital et sonde de détection gamma). Les 
paramètres et la survie ont été évalués par différentes analyses de régression logistique 
multiple selon Cox et la survie évaluée selon Kaplan Meier. 
Résultats 
Vingt-trois pourcent des patients présentaient au moins un ganglion sentinelle métastatique, 
ce qui était associé de façon significative à l'épaisseur selon Breslow (p<0.001). Le taux de 
succès de la biopsie du ganglion sentinelle était de 99 .1 % et sa morbidité de 7 .6%. Avec 
une durée médiane de suivi de 33 mois, la survie sans récidive à 5 ans était de 43% pour les 
patients avec un ganglion sentinelle positif et de 83.5% pour ceux avec un ganglion 
sentinelle négatif. La survie spécifique liée à la maladie à 5 ans était de 49% pour les 
patients avec un ganglion sentinelle positif et de 87.4% pour ceux avec un ganglion 
sentinelle négatif. Le taux de faux négatif de la biopsie du ganglion sentinelle était de 
8.6%. L'analyse multivariée a démontré que la survie sans récidive était significativement 
péjorée par: l'épaisseur selon Breslow (RR=5.6, p<0.001), un ganglion sentinelle positif 
(RR=5.0, p<0.001), et le sexe masculin (RR=2.9, p=0.001). La survie spécifique liée à la 
maladie était significativement diminuée par: un ganglion sentinelle métastatique (RR=8.4, 
p<0.001), le sexe masculin (RR=6.l, p<0.001), l'épaisseur selon Breslow (RR=3.2, 
p=0.013), et la présence d'une ulcération (RR=2.6, p=0.015). 
Conclusion 
La biopsie du ganglion sentinelle est une procédure fiable avec une haute sensibilité 
(91.4%) et une faible morbidité (7.6%). L'épaisseur selon Breslow était le seul facteur 
prédictif significatif pour le statut du ganglion sentinelle. La survie sans récidive était 
péjorée selon un ordre décroissant par : l'épaisseur selon Breslow, un ganglion sentinelle 
métastatique, et le sexe masculin. De façon similaire la survie spécifique liée à la maladie 
était péjorée par : un ganglion sentinelle métastatique, le sexe masculin, l'épaisseur selon 
Breslow, et une ulcération. Ces données renforcent le statut du ganglion sentinelle en tant 
que puissant moyen pour évaluer le stade tumoral ainsi que le pronostic. 
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Abstract 
Aim: To confirm the accuracy of sentine! node biopsy (SNB) procedure and its morbidity, and to investigate predictive factors for SN status 
and prognostic factors for disease-free survival (DFS) and disease-specific survival (DSS). 
Materials and methods: Between October 1997 and December 2004, 327 consecutive patients in one centre with clinically node-negative 
primary skin melanoma underwent an SNB by the triple technique, i.e. lymphoscintigraphy, blue-dye and gamma-probe. Multivariate 
logistic regression analyses as well as the Kaplan-Meier were performed. 
Results: Twenty-three percent of the patients had at least one metastatic SN, which was significantly associated with Breslow thickness 
(p < 0.001). The success rate of SNB was 99.1 % and its morbidity was 7.6%. With a median follow-up of 33 months, the 5-year DFS/ 
DSS were 43%/49% for patients with positive SN and 83.5%/87.4% for patients with negative SN, respectively. The false-negative rate 
of SNB was 8.6% and sensitivity 91.4%. On multivariate analysis, DFS was significantly worsened by Breslow thickness (RR = 5.6, 
p < 0.001), positive SN (RR = 5.0, p < 0.001) and male sex (RR = 2.9, p = 0.001). The presence of a metastatic SN (RR = 8.4, 
p < 0.001), male sex (RR = 6.1,p < 0.001), Breslow thickness (RR = 3.2,p = 0.013) and ulceration (RR = 2.6,p = 0.015) were significantly 
associated with a poorer DSS. 
Conclusion: SNB is a reliable procedure with high sensitivity (91.4%) and low morbidity. Breslow thickness was the only statistically sig-
nificant parameter predictive of SN status. DFS was worsened in decreasing order by Breslow thickness, metastatic SN and male gender. 
Similarly DSS was significantly worsened by a metastatic SN, male gender, Breslow thickness and ulceration. These data reinforce the SN 
status as a powerful staging procedure. 
© 2007 Elsevier Ltd. All rights reserved. 
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Introduction 
Sentinel node biopsy (SNB) is an important staging proce-
dure and may be a potential therapeutic approach in the man-
agement of melanoma. Metastatic spreading from a primary 
melanoma can be explained by two possible theories. 1 In the 
"marker" hypothesis, the primary melanoma metastasizes 
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simultaneously via lymphatic and haematogenous routes, 
so that the presence of regional lymph nodes metastases be-
comes a marker of the likelihood of systemic disease. In the 
"incubator" hypothesis, the primary melanoma targets re-
gional lymph nodes where metastatic cells may survive and 
slowly grow but remain latent before spreading to distant 
sites. According to this second theory, it was suggested that 
early removal of involved regional lymph nodes in early-
and intermediate-stage melanoma could prevent the progres-
sion of the metastases and thus improve survival. Four 
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prospective randomized studies2- 6 failed to support an over-
all survival benefit for patients undergoing elective lymph 
node dissection (ELND) instead of nodal observation, apart 
from subgroups of patients (tumor thickness between 1 and 
2 mm, tumor without ulceration, patients :S60 years of age 
and patients with limb melanomas) in the Intergroup Mela-
noma Surgical Trial. 5•6 The development of lymphatic map-
ping and the introduction of SNB in melanoma patients by 
Morton et al. 7 allowed to identify node-positive patients prior 
to complete node dissection and thus to select patients who 
might benefit from complementary selective lymph node dis-
section (SLND). The sentine! node (SN) is defined as the first 
node(s) directly draining lymph from the primary melanoma, 
and following this concept if early lymphatic metastases are 
present, they are to be found within this sentine! node. SNB is 
now a recognised approach, but not yet the standard of care 
for melanoma patients without clinically evident nodal me-
tastases. The knowledge of the SN status, which is included 
in the revised American Joint Committee on Cancer classifi-
cation, 8'9 permits an ultra staging of melanomas, provides an 
important survival prognostic parameter and prevents node-
negative patients from undergoing an unnecessary SLND 
that is associated with higher morbidity than SNB. 10 
Recently published interim results 11 from the ongoing 
Multicenter Selective Lymphadenectomy Trial (MSLT) 12 
showed that SNB with SLND in case of positive SN instead 
of observation with delayed lymph node dissection in case of 
nodal relapse significantly prolonged disease-free survival 
(DFS) but not disease-specific survival (DSS) in intermediate 
thickness (1.5-3.5 mm) primary melanomas. 11 
The aim of this prospective study was to analyse the re-
sults of the SNBs performed in our tertiary reference centre 
for melanoma, to verify the accuracy of the procedure and 
its morbidity, and to investigate predictive factors for SN 
status and prognostic factors for DFS and DSS. 
Materials and methods 
Patients 
Between October 1997 and December 2004 ail consec-
utive patients were included in a prospective systemic 
SNB program, and underwent an SNB performed by a sin-
gle surgical team at the Centre Hospitalier Universitaire 
Vaudois (CHUV) in Lausanne in Switzerland. The protocol 
of this study was accepted by the Institutional Ethical Com-
mittee. Inclusion criteria were primary skin melanoma 
> 1.00 mm without palpable adenopathy and absence of 
distant metastases (confirmed by CT scan or PET scan). 
Further patients with melanoma thickness :::; 1.00 mm in 
the presence of specific histopathologic factors, such as ul-
ceration, regression or Clark level IV N were also included. 
If metastases were detected in the SN(s), an SLND was pro-
posed. Patients were followed according to the stage of the 
disease at the outpatient clinic of the Oncology Unit with 
clinical and radiological regular examinations. 
Surgical technique and pathological analysis 
Ali patients' SN identification was performed according 
to the triple technique (lymphoscintigraphy, blue-dye 
and gamma-probe). Lymphoscintigraphy was performed on 
the day before surgery. Injections of m99Tc-nanocolloid 
(Nanocoll, Amersham Health, UK) around the excision-
biopsy scar followed by dynamic and static imaging were 
performed to identify the draining lymphatic vessels and 
SN(s). The surface location of the SN(s) was marked after 
localisation with a hand-held gamma-probe (Scintiprobe® 
Pol.Hi.Tech, then Neoprobe gamma neo2000®) and/or an 
external 57 Cobalt pen. The day of surgery 2 ml of patent 
blue V (bleu patenté violet, Laboratoire Guerbet, France) 
were injected intradermally in four points around the scar 
or the primary tumor. Surgery was directed by the same 
gamma-probe with the systematic exploration of all possible 
basins. The SN was defined as any blue node, the node with 
the highest radioactive count, any node with > 10% count rate 
of the most radioactive node. Any enlarged (> 1 cm) suspi-
cious node and some adjacent nodes (mainly for anatomical 
reason) were also dissected. SNB was followed by scar wide-
excision (WE) with usual safety margins13•14 (1 cm and 2 cm 
for melanoma, <1 mm and ::::1 mm thick, respectively). 
SN(s) were sent fresh or in formaldehyde solution directly 
to the Department of Pathology. Lymph nodes were bivalved 
and paraffin embedded. Three slices were eut for H-E and 
immunohistochemistry staining (Melan A and protein 
SlOO) at a regular 50 microns interval for at least six times. 
No PCR analysis has been performed. The SLND's nodes 
were only processed with H-E staining. 
Statistical ana/ysis 
Quantitative variables were compared using the Student 
or the Wilcoxon test. Categorical variables were compared 
using the x2 test. A multivariate logistic regression mode! 
was used for clinicopathological characteristics predictive 
of SN metastases. Survival analysis involved the Kaplan-
Meier method combined with log-rang test and multivariate 
Cox's proportional hazard regression models. Statistical 
analyses were performed with R software (Ihaka and Gentle-
man, 1996). p-Values <0.05 were considered statistically 
significant. 
Results 
During the study period, 327 consecutive patients with 
primary skin melanoma underwent an SNB and were in-
cluded in this study. 
Clinicopathologic characteristics 
The 327 patients' clinicopathologic characteristics are 
presented on Table 1. Male and female patients (54% vs. 
46%) had similar mean ages (55 years vs. 52 years). The 51 
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Table 1 
Clinicopathologic characteristics of 327 patients 
Characteristic 
Male/female 
Age mean/median (range) 
Melanoma subtype 
Superficial spreading (SSM) 
Nodular (NM) 
Acral lentiginous (ALM) 
Others 
Breslow thickness, 
mean/median (range) 
:<=LOO mm 
1.01-2.0 mm 
2.01-4.0mm 
>4.0mm 
Ulceration 
Pre sent 
Absent 
Primary melanoma location 
Head and neck 
Trunk 
Extremity 
Lymph node basin 
l 
>l 
Patients number 
175/152 
53.5/54 (13-85) 
147 
90 
36 
54 
2.24/1.70 (0.25-12.00) 
51 
146 
96 
34 
88 
239 
28 
131 
168 
258 
69 
patients included in the Tl group (Breslow thickness 
::; 1.0 mm) presented with a Breslow thickness close to 
1.01 mm (n = 6), ulceration (11 = 3), Clark level IV 
(11 = 23), Clark level IV and ulceration (n = 3), regression 
(n = 10), status after laser treatment (n = 1) and further pa-
tients between 20 and 30 years (n = 5) were also included 
due to their young age. 
Sentine! node identification 
Among those 327 patients a total of 401 nodal basins 
were mapped: 258, 64 and five patients had one, two and 
three synchronous nodal basin, respectively. Inguinal and 
iliac basins were considered as two distinct basins. A total 
of 645 SNs were identified (1.97 SN/patient and 1.61 SN/ 
nodal basin). 
Sentine! node biopsy morbidity 
The success rate of SNB was 99 .1 % . The three patients 
with SNB's failure had two synchronous basins each, with 
a failed SNB in only one of the two. The overall 
SNB + WE morbidity was 7.6% (Table 2). The only case 
of blue-dye anaphylaxis quickly responded to steroids 
and antihistamines, and the three cases of blue-dye skin re-
actions quickly responded to antihistamines. No surgery-
related death occurred. 
Sentine! node' s characteristics 
Metastases to SNs were detected in 74 out of 327 patients 
and in 94 out of 645 dissected SNs. Fifty-nine patients had 
Table 2 
Complications associated with sentine! node biopsy 
Complication 
Lymphocoele 
Lymphedema 
Blue-dye allergy: urticaria/anaphylaxis 
Wound infection 
Lymphocoele infection 
Wound dehiscence 
Pulmonary embolism 
Total 
Patient number 
10 
6 
3/1 
2 
1 
25 
one positive SN, 11 had two positive SNs, three had three pos-
itive SNs and one had four positive SNs. There were only two 
cases in which positive SNs were found in two different lym-
phatic basins. Micrometastases to SNs were distributed 
according to Starz classification15 defined on Table 3. There 
were 253 SO patients, 26 SI, 18 S2 and 30 S3. 
Predictive factors of sentine! node metastases 
Positive(s) SN(s) were found in 23% of patients. Mean 
Breslow thickness of primary melanoma was 1.95 mm for 
SN-negative cases and 3.22 mm for SN-positive cases. Three 
Tl patients had one or two metastatic SN. One with a 0.78 mm 
Clark IV melanoma had two metastatic SN and two with 
0.95 mm Clark IV and 1.0 mm Clark III melanomas had 
each one positive SN. No Tl patients included due to regres-
sion (11=16) presented with a metastatic SN. 
Univariate analysis of risk factors of metastatic SN is 
presented on Table 4. Multivariate logistic regression anal-
ysis for predictive factors of SN metastases showed that 
only Breslow thickness was statistically significant (T3: 
p = 0.009, T4: p < 0.001). 
Tumor recurrence and diseasejree survival 
With a median follow-up of 33 months (range: 12-95 
months), 19% of patients (34 positive SN and 28 negative 
SN patients) presented tumor recurrences at a median time 
of 30 months (mean: 34 months). Overall 46% positive SN 
and 11 % negative SN patients recurred. 
Table 3 
Definition of Starz classification" 
so 
SI 
S2 
S3 
n=O 
1 :<=11 :'=2 
Il >2 
Il >2 
" According to S-staging concept. 15 
0 
:'=l 
:'=l 
>l 
b 11, Number of 1-mm-thin sentine! lymph node slices with detectable 
tumor cells. 
c d, Maximum distance of tumor cells to the interior margin of the lyrnph 
node capsule. 
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Table 4 
Sentine! node (SN) status according to clinicopathological characteristics 
Number of patients: 327 SN-positive, SN-negative, p-Value 
74 253 
Gender NS 
Male 43 132 
Fe male 31 121 
Age NS 
:C-.65 years 21 70 
<65 years 53 183 
Melanoma subtype 0.016 
Superficial spreading (SSM) 27 120 
Nodular (NM) 31 59 
Acral lentiginous (ALM) 8 28 
Others 8 46 
Breslow thickness, mm <0.001 
:"'.LOO 3 48 
1.01-2.0 23 123 
2.01-4.0 32 64 
>4.0 16 18 
Ulceration 0.003 
Present 30 58 
Absent 44 195 
Primary melanoma location NS 
Head and neck 4 24 
Trunk 35 96 
Extremities 35 133 
Lymph node basin NS 
l 55 203 
>1 19 50 
NS, not significant statistically. 
A false-negative result of SNB was defined as a nodal re-
currence in the previously dissected regional basin without 
previous local or in-transit metastases. 16 Our SNB's false-
negative rate was 8.6% (7/81) and its sensitivity was 91.4%. 
We combined the reporting of local and regional metastases 
(satellite, in-transit (ITM) and nodal metastases), distinguish-
ing them from distant metastases. Overall 62 patients re-
curred, 46 with loco-regional recurrence first (20 ITM, 18 
nodal and eight local). SN-positive and SN-negative patients 
presented no significant difference concerning the first site of 
recurrence (loco-regional vs. distant). The incidence of ITM 
as site of first recurrence was 6.1 % and was significantly 
higher (p < 0.01) among metastatic SN patients (10 out of 
74) compared to negative SN patients (10 out of 253). None 
of the 51 T 1 patients with a metastatic SN presented a tumor 
recurrence. The 5-year DFS was 43% (95%CI 0.306-
0.604) for patients with positive SN and 83.5% (95%CI 
0.776-0.989) for patients with negative SN. On univariate 
analysis (Fig. 1) metastatic SN (p < 0.001), Breslow index 
(p < 0.001), male sex (p < 0.001), ulceration (p < 0.001), 
age ;=::65 years (p = 0.035) and melanoma type (ALM, 
P = 0.03) were significantly associated with tumor recur-
rence. Starz (SO vs. SI vs. S2 vs. S3), tumor location (trunk 
vs. extremities vs. head and neck) and number of lymph 
node basin (1 vs. > 1) were not significant. On multivariate 
analysis (Table 5) DFS was significantly worsened by Bre-
slow index (p < 0.001), positive SN (p < 0.001) and male 
sex (p = 0.001). 
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Figure 1. Disease-free survival according to sentine! node (SN) status (cal-
culated from date of SN biopsy). 
Disease-specijic survival 
Thirty-five patients died of melanoma's progression and 
five died of another cause. The 5 years DSS was 49.1 % 
(95%CI 0.809-0.948) for SN-positive patients and 87.4% 
(95%CI 0.340-0.709) for SN-negative patients. On univar-
iate analysis (Fig. 2) positive SN (p < 0.001), Breslow 
thickness (p < 0.001), male sex (p = 0.003) and ulceration 
(p = 0.006) were significantly associated with melanoma-
related death. Starz, age, tumor type, tumor location and 
number of lymph node basin were not significant. On mul-
tivariate analysis (Table 6) the presence of a metastatic SN 
(p < 0.001), male sex (p < 0.001), Breslow thickness in T3 
(p = 0.013) and ulceration (p = 0.015) were significantly 
associated with a poorer DSS. 
Positive sentine! node subgroup analysis 
Among the 74 positive SN patients, 64 underwent an 
SLND (59 and five patients underwent an SLND of one 
and two nodal basins, respectively), six refused this second 
operation and four were not proposed this operation. In 
17% of cases (11/64 patients and 12/69 nodal basins) positive 
non-SNs were found. Risk factors ofnon-sentinel nodes17•18 
could not be evaluated in this study due to the small number 
of patients. On univariate analysis tumor recurrence was sig-
nificantly associated with Breslow index (p < 0.001) and 
Table 5 
Multivariate Cox's analysis of disease-free survival 
RR 95%CI p-Value 
Breslow thickness 5.61 2.27-13.90 <0.001 
Positive SN 5.00 2.84-8.82 <0.001 
Male 2.91 1.57-5.38 0.001 
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Figure 2. Disease-specific survival according to sentine! node (SN) status. 
male gender (p = 0.032). On univariate analysis DSS was 
significantly associated with male gender (p = 0.019) and 
Breslow index (p = 0.025). 
Discussion 
Our present study is single institution based and surgical 
procedures were performed by a single surgical team. In 
a review of literature we only found two other reports 
with more than 200 patients 11 •14 that also included prognos-
tic factors' multivariate analysis for both DFS and DSS. In 
the current study we established that DFS was worsened in 
order of significance by Breslow index, metastatic SN and 
male gender. We also showed that in decreasing order a met-
astatic SN, male gender, Breslow thickness and ulceration 
were significantly associated with a poorer DSS. Morton 
et al. 11 and Gershenwald et al. 19 both showed that meta-
static SN followed by increasing Breslow thickness and 
the presence of ulceration were significant predictors for 
DFS. Concerning DSS they both established that metastatic 
SN followed by Breslow thickness were significant prog-
nostic factors. Morton et al. 11 found that additional inde-
pendent prognostic factors were age 2':60 years for DFD, 
and ulceration as well as truncal location for DSS. Thus 
the SN status and the Breslow thickness are the most signif-
icant independent factors for both DFD and DSS. If we 
consider only SNB literature, the poorer prognosis associ-
ated with male gender for both DFS and DSS in this study 
Table 6 
Multivariate Cox's analysis of disease-specific survival 
RR 95%CI p-Value 
Positive SN 8.38 3.65-19.26 <0.001 
Male 6.14 2.42-15.56 <0.001 
Breslow index (T3) 3.18 1.28-7.91 0.013 
Ulceration 2.60 1.21-5.61 0.015 
has only been reported by Scoggins et a!. 20 Since men hav-
ing undergone SNB had a worse prognosis than women and 
that metastatic SN was the most powerful predictor of sur-
vival, one could suspect that men would be at higher risk of 
having a metastatic SN. But we established that gender was 
not predictive of the SN status. Our analysis of the meta-
static SN subgroup showed that once the SN was positive 
only the Breslow thickness and male gender were signifi-
cant predictive factors for both DFS and DSS. Unlike Starz 
et al., 15 who reported that S classification was an indepen-
dent factor inftuencing distant metastasis and survival, we 
found that S classification was not significant for prediction 
of both DFS and DSS. Other classifications of tumor 
burden in SN have been developed in order to evaluate 
the risk of positive non-SN,21 •22 and they will be subject 
to further analysis. 
Sentine! node biopsy and ifs complications 
SNB has been designed as a staging procedure permitting 
to avoid the morbidity ofunnecessary ELND in negative SN 
patients and might be useful in the future to study nove! ad-
juvant therapies. The SN status is reported in various multi-
variate studies as the strongest independent prognostic factor 
for DFS, 11 •19•23- 26 DSS 11 •19 and overall survival (OS).27- 29 
With the use of the triple technique, we obtained an SNB suc-
cess rate of 99 .1 % comparable to important series that also 
included head and neck melanomas. 12•23 The false-negative 
rate of this procedure was 8.6% which is situated within 
· · IO 16 24 27-32 the range ( 4. 7-11 % ) reported m the hterature. · · · 
The SNB-associated complications rate in our study was 
7.6%. This is between the values reported in the Sunbelt 
Melanoma Trial (4.6%)31 and in the Multicenter Selective 
Lymphadenectomy Trial 1 (10.1 %) where the complication 
rate increased to 37.2% with the addition of SLND after 
SNB. 10 Our main complications were lymphocoele and 
lymphedema. The 1.8% lymphedema incidence was similar 
to the 1.7% lymphedema incidence found by Wrone et al. 32 
Allergie blue-dye anaphylaxis occurred in 0.3% which is 
slightly lower than the 0.7% in Leong et al. experience.33 
However, the comparison is not completely valid as we 
used patent blue V while these authors used isosulfan (lym-
phazurine ). We observed that the incidence ofITM as site of 
first recurrence was 6.1 %, and that it was significantly higher 
among metastatic SN patients (13.5%) compared to negative 
SN patients (4%) as reported in other studies. 34•35 The latter 
can be explained by the fact that metastatic SNs are found 
among patients whose tumor has already developed a meta-
static potential. SNB is thus a safe procedure associated with 
a low morbidity and no mortality. 
Predictive factors of sentine! node status 
There are only few published studies that have evaluated 
predictive factors of SN metastases by multivariate analy-
sis. McMasters et a!.36 found that Breslow thickness, Clark 
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level, ulceration and age ::;60 years were significant predic-
tors of SN metastases. Wagner et al.37 found that a Breslow 
thickness eut point ~ 1.25 mm, ulceration and high mitotic 
index were significant predictive factors of SN positivity. 
Rousseau et al.38 found that Breslow thickness, ulceration, 
age ::;so years and truncal location were significant predic-
tors of SN metastases. Other histopathological factors pub-
lished by others such as mitotic index, 37 tumor infiltrating 
lymphocytes,39 or angiolymphatic invasion40 were also pre-
dictive of SN positivity. Our multivariate logistic regression 
analysis for predictive factors of SN metastases showed that 
only Breslow thickness was statistically significant (T3: 
p = 0.009, T4: p < 0.001). Ulceration (p = 0.071) and trun-
cal location (p = 0.066) were close to reach statistical 
significance. 
Breslow thickness and ulceration are constantly reported 
as predictive factors of metastatic SN in various univariate 
analyses. 25•27•36- 38 In our study we also found that Breslow 
thickness stratified according to the AJCC classification 
and ulceration were significantly correlated with SN posi-
tivity. Nodular melanoma was also a predictive factor of 
SN positivity which is consistent with Nowecki et al. 
experience. 27 
Indications of sentine[ node biopsy 
The indication of SNB in thin (::; 1 mm) cutaneous mela-
noma is still controversial. In the new AJCC staging system,8 
tumors ::; 1 mm thick are classified as T 1 a if they are non-
ulcerated and Tl b if they are ulcerated or Clark IV or V. 
This is based on the reported 10 years survival rates of 
87.9% for the Tla group and of 83.1 % for the Tlb group.41 
The rate of tumor-positive SN in melanoma ::; 1 mm thick is 
reported to be 3% in two published reports.42·43 In the cur-
rent study we showed that 6% of melanoma ::; 1 mm thick 
had metastatic SN, but ail SLND were tumor-free. During 
a mean follow-up of 33 months of these Tl patients there 
was no relapse and no patient died of the disease. The pres-
ence of regression as inclusion criteria for SNB is also ques-
tionable; it has been described either as an unfavourable44•45 
or as a protective46 prognostic factor. Moreover, Topping 
et al.47 reported in their study that ail patients having histo-
logical features of regression had a negative SN. In our study 
ail the patients presenting with regression associated with 
a Breslow thickness ::;1 mm (n = 16) had a negative SN 
and did not relapse. This observation, despite the small num-
ber of patients, could suggest that regression associated to 
a Breslow thickness < 1 mm should not be considered as 
an inclusion criterion anymore. 
Conclusion 
This present single institution study confirms that SNB is 
a reliable and reproducible procedure with high sensitivity 
(91.4%) as well as a low morbidity (7.6%). Our multivariate 
logistic regression analysis for predictive factors of SN 
metastases showed that only Breslow thickness was statisti-
cally significant. We concluded that DFS was worsened in 
order of significance by Breslow index, metastatic SN and 
male gender. And finally we found that in decreasing order 
a metastatic SN, male gender, Breslow thickness and 
ulceration were significantly associated with a poorer DSS. 
These data reinforce the SN status as a powerful staging 
procedure. 
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